Shares of Bausch Health Companies Inc. BHC gained 2.36% after the company reported better-than-expected fourth-quarter ...

Discover why combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe ...

Real-life studies point out that <15% of patients eligible for pTIPS ultimately undergo transjugular intrahepatic portosystemic shunt (TIPS) due to concerns about hepatic encephalopathy (HE). The ...

Generic Xifaxin is indicated for the reduction in risk of overt hepatic encephalopathy recurrence in adults and irritable bowel syndrome with diarrhea. Ozempic has been approved to reduce the risk ...

Rifaximin is under clinical development by Alfasigma and currently in Phase III ... caused by noninvasive strains of Escherichia coli and reduction in risk of overt hepatic encephalopathy. Xifaxanta ...

Morningstar brands and products Company Portfolio ...

There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients. Caution should be ...

Bausch Health (BHC) Companies and Salix Pharmaceuticals acknowledged that the Centers for Medicare and Medicaid Services has selected XIFAXAN 550 mg tablets as one of the medicines for the second ...

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.